TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39634788

Group type: EXPERIMENTAL
Intervention: Retinol Isotope Dilution (RID)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Population-based modeling
Number of subjects: 0
Study: 39635024

Group type: COMPARATOR
Intervention: Fecal microbiota transplantation (FMT), five 100 ml doses prepared from 30 g stool from an unrelated healthy donor, administered daily to the upper gastrointestinal tract.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group receiving standard of care (CS).
Number of subjects: 44
Study: 39635465

Group type: EXPERIMENTAL
Intervention: Macitentan 10 mg once daily for 12 weeks
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 39635498

Group type: EXPERIMENTAL
Intervention: Exercising into pain
Number of subjects: 43

Group type: COMPARATOR
Intervention: Exercising without pain
Number of subjects: 43
Study: 39636024

Group type: EXPERIMENTAL
Intervention: Oral moxifloxacin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 0
Study: 39636092

Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction exercise (LL-BFRE)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Sham BFRE
Number of subjects: 21
Study: 39636343

Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg twice daily
Number of subjects: 370

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study: 39636384

Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound (SR-US) imaging after bolus injection of microbubbles at clinical concentration
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Super-resolution ultrasound (SR-US) imaging
Number of subjects: 47
Study: 39636391

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39636496

Group type: EXPERIMENTAL
Intervention: Overdose education and direct provision of naloxone to incarcerated individuals upon release
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Initiating medications for opioid use disorder (MOUD) prior to release
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Linkage to ongoing MOUD treatment in the community
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Peer support-facilitated treatment retention efforts
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Emergency housing in the immediate post-incarceration period
Number of subjects: 3
Study: 39636502

Group type: EXPERIMENTAL
Intervention: Remote, tablet-based patient video education intervention focused on cancer care coordination
Number of subjects: 19
Study: 39636623

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of conventional type 1 dendritic cells (cDC1), 6 times weekly, followed by paclitaxel (80 mg/m2, intravenously, 12 times weekly), trastuzumab (8 mg/kg loading dose, then 6 mg/kg), and pertuzumab (840 mg loading dose, then 420 mg) every 3 weeks for 6 cycles starting from day 1 of cDC1 injections.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intratumoral delivery of conventional type 1 dendritic cells (cDC1)
Number of subjects: 12
Study: 39636638

Group type: EXPERIMENTAL
Intervention: Psilocybin, 25 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Niacin, 100 mg
Number of subjects: 30
Study: 39636667

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) training for ACLS
Number of subjects: 102

Group type: COMPARATOR
Intervention: Traditional lecture-based instruction (Control)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Augmented Reality (AR) training for ACLS (subgroup analysis)
Number of subjects: 102
Study: 39636672

Group type: EXPERIMENTAL
Intervention: Essential Coaching for Every Mother Tanzania (ECEM-TZ) - standardized text messages from birth to 6 weeks postpartum
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 124
Study: 39636679

Group type: EXPERIMENTAL
Intervention: Oral screen training for 12 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no oral screen training)
Number of subjects: 24
Study: 39636682

Group type: EXPERIMENTAL
Intervention: Current medical decision-making participation self-efficacy
Number of subjects: 0
Study: 39636875

Group type: EXPERIMENTAL
Intervention: GHK intervention (multi-component and multi-setting intervention)
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1600
Study: 39637186

Group type: EXPERIMENTAL
Intervention: Active tDCS (4 mA for 20 minutes)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 45
Study: 39637307

Group type: EXPERIMENTAL
Intervention: Venetoclax plus hypomethylating agents
Number of subjects: 209
Study: 39637726

Group type: EXPERIMENTAL
Intervention: Brivaracetam (≤5 mg/kg/day, ≤200 mg/day)
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Brivaracetam
Number of subjects: 185
Study: 39637747

Group type: EXPERIMENTAL
Intervention: Video discharge instructions
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Booklet discharge instructions
Number of subjects: 144

Group type: COMPARATOR
Intervention: Verbal discharge instructions
Number of subjects: 144
Study: 39637767

Group type: COMPARATOR
Intervention: BI 409306
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Machine-learning model (14-day monitoring)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Machine-learning model (Trial-End timepoint)
Number of subjects: 235
Study: 39637878

Group type: EXPERIMENTAL
Intervention: LEAPS early childhood care and education programme
Number of subjects: 3858

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 3858
Study: 39637881

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg
Number of subjects: 1372

Group type: EXPERIMENTAL
Intervention: Filgotinib 100 mg
Number of subjects: 1372

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1372
Study: 39637900

Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant
Number of subjects: 127
Study: 39637944

Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D) as neoadjuvant treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D) as definitive treatment
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Tremelimumab + Durvalumab (T300/D)
Number of subjects: 35
Study: 39638148

Group type: EXPERIMENTAL
Intervention: Oral L-citrulline supplementation
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 39638222

Group type: EXPERIMENTAL
Intervention: Moderately fit individuals (above average peak oxygen uptake)
Number of subjects: 1565

Group type: COMPARATOR
Intervention: Unfit individuals (below average peak oxygen uptake)
Number of subjects: 1565
Study: 39638275

Group type: EXPERIMENTAL
Intervention: Catheter-directed therapy (CDT) plus anticoagulation
Number of subjects: 500

Group type: COMPARATOR
Intervention: Anticoagulation alone (No-CDT group)
Number of subjects: 500
Study: 39638292

Group type: EXPERIMENTAL
Intervention: Titanium-prepared platelet-rich fibrin (T-PRF)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral (DBBM)
Number of subjects: 10
Study: 39638429

Group type: EXPERIMENTAL
Intervention: Community-based interventions and improved access to inpatient care
Number of subjects: 106259

Group type: EXPERIMENTAL
Intervention: Annual CVD incidence
Number of subjects: 106259

Group type: EXPERIMENTAL
Intervention: Age-standardised and sex-standardised CVD incidence rate
Number of subjects: 106259

Group type: EXPERIMENTAL
Intervention: CVD mortality
Number of subjects: 106259
Study: 39638553

Group type: EXPERIMENTAL
Intervention: Carfilzomib-lenalidomide-dexamethasone (KRd)
Number of subjects: 50
Study: 39638564

Group type: EXPERIMENTAL
Intervention: Psychological-based intervention (3 sessions)
Number of subjects: 46
Study: 39638585

Group type: EXPERIMENTAL
Intervention: ACTION (Acceptance and Commitment Therapy Intervention when Opioids are Necessary)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 40
Study: 39638587

Group type: EXPERIMENTAL
Intervention: Preliminary infection diagnosis by physicians
Number of subjects: 954
Study: 39638591

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not provided)
Number of subjects: 92
Study: 39638596

Group type: EXPERIMENTAL
Intervention: Standard surgical treatment followed by application of autologous bioartificial palate mucosa
Number of subjects: 15

Group type: COMPARATOR
Intervention: Standard surgical treatment (control group)
Number of subjects: 15
Study: 39638602

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control
Number of subjects: 95
Study: 39638782

Group type: EXPERIMENTAL
Intervention: Combination of pembrolizumab with bevacizumab and oral cyclophosphamide
Number of subjects: 40
Study: 39639088

Group type: EXPERIMENTAL
Intervention: Afatinib (40 mg daily)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: ctDNA monitoring
Number of subjects: 39
Study: 39639184

Group type: EXPERIMENTAL
Intervention: CPMRx mobile application (electronic monitoring blister pack plus mobile application)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (electronic monitoring blister pack only)
Number of subjects: 98
Study: 39639281

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy LDL/HDL ratio
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Pre-pregnancy TC/HDL ratio
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of elevated LDL/HDL ratio
Number of subjects: 767

Group type: EXPERIMENTAL
Intervention: Baseline age, fasting plasma glucose, and LH
Number of subjects: 767
Study: 39639282

Group type: EXPERIMENTAL
Intervention: Creative writing intervention combined with standard treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Pilot RCT for participants aged 18-35 with schizophrenia spectrum disorders
Number of subjects: 300
Study: 39639285

Group type: COMPARATOR
Intervention: Clinic
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-WIC
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-RDN
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-WIC-RDN
Number of subjects: 240

Group type: COMPARATOR
Intervention: Clinic and Clinic-RDN
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Clinic-WIC and Clinic-WIC-RDN
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Secondary endpoints
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Implementation outcome measures
Number of subjects: 240
Study: 39639405

Group type: EXPERIMENTAL
Intervention: 12-week caloric restriction combined with strength and HIIT training
Number of subjects: 23
Study: 39639560

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Extracorporeal carbon dioxide removal (ECCO)
Number of subjects: 18
Study: 39639890

Group type: EXPERIMENTAL
Intervention: Swept-source OCT angiography (SS-OCTA) metrics
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: OCTA examinations and microaneurysm counting using CFP
Number of subjects: 60
Study: 39639915

Group type: EXPERIMENTAL
Intervention: Method B (catheter advanced after retracting integral stylet by 6 cm)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Method A (catheter advanced with integral stylet extending along its entire length)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Method B (pilot study in patients)
Number of subjects: 25
Study: 39639945

Group type: EXPERIMENTAL
Intervention: Behavioral smartphone data (passively sensed)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lower step count
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Slower walking rate
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lower normalized location entropy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: More time at home
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Lower distances traveled
Number of subjects: 131
Study: 39640074

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 165
Study: 39640075

Group type: EXPERIMENTAL
Intervention: Uchasingihwan (UCSGH) 2.5 g granule three times a day for six weeks
Number of subjects: 74

Group type: COMPARATOR
Intervention: loxoprofen 60 mg tablet three times a day for six weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Uchasingihwan (UCSGH)
Number of subjects: 74

Group type: COMPARATOR
Intervention: loxoprofen
Number of subjects: 74
Study: 39640185

Group type: EXPERIMENTAL
Intervention: Turkish version of the Medial Tibial Stress Syndrome score (MTSS-Tr)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Turkish version of the 36-Item Short-Form Survey (SF-36-Tr)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) for pain
Number of subjects: 48
Study: 39640219

Group type: EXPERIMENTAL
Intervention: Home-based exercise programme (HBEP)
Number of subjects: 31
Study: 39640300

Group type: EXPERIMENTAL
Intervention: Circuit Training Program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39640621

Group type: EXPERIMENTAL
Intervention: Double plasma molecular adsorption system (DPMAS) and low-volume plasma exchange (LPE) on three occasions
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving plasma exchange (PE) three times
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DPMAS + LPE
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group receiving PE
Number of subjects: 60
Study: 39640932

Group type: EXPERIMENTAL
Intervention: WASH
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: IYCF
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Standard-of-care
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Combined WASH & IYCF
Number of subjects: 1002
Study: 39640961

Group type: EXPERIMENTAL
Intervention: HEMO-AI using images from a 12.2 megapixel camera
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: HEMO-AI using images from a Pixel 6 camera
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: HEMO-AI with synthetic data supplementation
Number of subjects: 823

Group type: EXPERIMENTAL
Intervention: HEMO-AI overall detection capability
Number of subjects: 823
Study: 39641169

Group type: EXPERIMENTAL
Intervention: Daily avocado consumption
Number of subjects: 0
Study: 39641193

Group type: EXPERIMENTAL
Intervention: 18F-mFBG PET imaging
Number of subjects: 27
Study: 39641307

Group type: EXPERIMENTAL
Intervention: South Asians with T2DM
Number of subjects: 96
Study: 39641404

Group type: EXPERIMENTAL
Intervention: Daridorexant 25 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daridorexant 50 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Daridorexant (both doses)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 39641509

Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Number of subjects: 74
Study: 39641640

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) goggles
Number of subjects: 91

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 91
Study: 39641725

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI with current generation drug-eluting stents (DES)
Number of subjects: 1500

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI
Number of subjects: 1500
Study: 39641816

Group type: EXPERIMENTAL
Intervention: Silver diamine fluoride (SDF)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Atraumatic restorative treatment (ART)
Number of subjects: 118
Study: 39641856

Group type: EXPERIMENTAL
Intervention: Anidulafungin (200 mg on day 1, then 100 mg daily)
Number of subjects: 20
Study: 39641864

Group type: EXPERIMENTAL
Intervention: Microbiome analysis using OMNIgene-GUT
Number of subjects: 0
Study: 39641926

Group type: EXPERIMENTAL
Intervention: DPYD/UGT1A1 pharmacogenetic-informed therapy
Number of subjects: 563

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 563
Study: 39641985

Group type: EXPERIMENTAL
Intervention: Self-help program intervention delivered via an automated conversational agent on WhatsApp
Number of subjects: 1345

Group type: COMPARATOR
Intervention: Active control group with access to evidence-based wellness resources available online
Number of subjects: 1345
Study: 39642162

Group type: EXPERIMENTAL
Intervention: Blue-depleted evening light environment
Number of subjects: 476

Group type: COMPARATOR
Intervention: Standard evening light environment
Number of subjects: 476
Study: 39642315

Group type: EXPERIMENTAL
Intervention: Fitusiran (50 mg or 80 mg)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fitusiran (AT-based dose regimen)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Fitusiran prophylaxis
Number of subjects: 34
Study: 39642329

Group type: EXPERIMENTAL
Intervention: Remote symptom and adherence monitoring app
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: App + feedback
Number of subjects: 163

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 163
Study: 39642360

Group type: EXPERIMENTAL
Intervention: Text4Strength (automated text messages)
Number of subjects: 223
Study: 39642375

Group type: EXPERIMENTAL
Intervention: Mindful breathing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Guided breathing
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Breath counting
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Resting state
Number of subjects: 51

Group type: COMPARATOR
Intervention: All breathing training conditions
Number of subjects: 51
Study: 39642746

Group type: EXPERIMENTAL
Intervention: Dietary Inflammatory Index (DII) score
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: DII score as a continuous variable
Number of subjects: 582
Study: 39642774

Group type: COMPARATOR
Intervention: Lenvatinib plus Pembrolizumab
Number of subjects: 3

Group type: COMPARATOR
Intervention: Lenvatinib plus Everolimus
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 3
Study: 39642783

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure Therapy with financial incentives (PE+)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Prolonged Exposure Therapy (PE)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 52
Study: 39642889

Group type: EXPERIMENTAL
Intervention: EZH2 inhibitors
Number of subjects: 0
Study: 39642902

Group type: EXPERIMENTAL
Intervention: Infusion of autologous gene-corrected haematopoietic stem cells
Number of subjects: 8
Study: 39642900

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 616

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 616
Study: 39642938

Group type: EXPERIMENTAL
Intervention: ElderTree intervention
Number of subjects: 346

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 346
Study: 39643110

Group type: EXPERIMENTAL
Intervention: Count of neonatal morbidities (Serious brain injury, Bronchopulmonary dysplasia, Severe retinopathy of prematurity)
Number of subjects: 3794
Study: 39643207

Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639

Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study: 39643644

Group type: EXPERIMENTAL
Intervention: Cold acclimation with shivering
Number of subjects: 15
Study: 39643869

Group type: EXPERIMENTAL
Intervention: SWELE program (16-week program combining unstructured outdoor play activities with mindfulness-based interventions)
Number of subjects: 0
Study: 39644340

Group type: COMPARATOR
Intervention: Functional bandage (n=51)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Non-restraint measures (n=62)
Number of subjects: 113
Study: 39644455

Group type: EXPERIMENTAL
Intervention: 30 s-STS
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: 5r-STS
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Both 30 s-STS and 5r-STS
Number of subjects: 376
Study: 39644535

Group type: EXPERIMENTAL
Intervention: HAI-FUDR (Hepatic Arterial Infusion of Floxuridine)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard systemic chemotherapy only (non-HAI group)
Number of subjects: 92
Study: 39644858

Group type: EXPERIMENTAL
Intervention: Aromatic solution (lavender and ginger oil) applied as a mouth spray at 0, 2, 4, 6, and 8 hours postoperatively
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo mouth spray
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 110
Study: 39644890

Group type: EXPERIMENTAL
Intervention: Anodal tDCS to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Sham stimulation to the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 241
Study: 39644907

Group type: EXPERIMENTAL
Intervention: Mitapivat 50 mg
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mitapivat 100 mg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 39644913

Group type: EXPERIMENTAL
Intervention: FFR-guided PCI plus TAVI
Number of subjects: 172

Group type: COMPARATOR
Intervention: SAVR plus CABG
Number of subjects: 172
Study: 39645016

Group type: EXPERIMENTAL
Intervention: Sotatercept (activin signaling inhibitor)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Sotatercept
Number of subjects: 429
Study: 39645140

Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the Nucleus Accumbens (NAc)
Number of subjects: 6
Study: 39645178

Group type: EXPERIMENTAL
Intervention: PAMM in A-AION
Number of subjects: 32

Group type: COMPARATOR
Intervention: Peripapillary IRF/SRF in NA-AION
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Combined biomarkers
Number of subjects: 32
Study: 39645236

Group type: EXPERIMENTAL
Intervention: Acalabrutinib, Venetoclax, and Obinutuzumab (AVO)
Number of subjects: 72
Study: 39645254

Group type: EXPERIMENTAL
Intervention: IVF with assessment of niche presence via SHG and TVS
Number of subjects: 250
Study: 39645257

Group type: EXPERIMENTAL
Intervention: NIRS-based NFT in a VR classroom setting
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional computerised cognitive training (active control)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 138
Study: 39645270

Group type: EXPERIMENTAL
Intervention: Continuation of β-blocker therapy
Number of subjects: 2540

Group type: COMPARATOR
Intervention: Discontinuation of β-blocker therapy
Number of subjects: 2540